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Stabilisation of metastable polymorphs: the case
of paracetamol form III†
Richard Telford,a Colin C. Seaton,a Alexander Clout,b Asma Buanz,b
Simon Gaisford,b Gareth R. Williams,b Timothy J. Prior,c Chidera H. Okoye,d
Tasnim Munshid and Ian J. Scowen*d
The design of a melt synthesis of the first air-stable formulation of
the metastable form III of paracetamol is derived from thermo-
spectroscopic and thermo-diﬀraction experiments. Melt crystallisa-
tion in the presence of b-1,4-saccharides produces form III selectively
and the excipients appear to act as stabilising ‘active’ templates of the
metastable polymorph.
Accessing and stabilising metastable polymorphic forms of active
pharmaceutical ingredients remains a major challenge in pharma-
ceutical product innovation.1,2 While systemic approaches to
polymorphic diversity in organic solids remain elusive, we report
here studies into the polymorphism of paracetamol that indicates
a promising role for the ‘excipient’ matrix to direct and stabilise
metastable forms and the importance of in situ characterisation of
polymorphism for formulation design.
Paracetamol exists in three polymorphic forms; a stable
phase (I) and two metastable phases (II, III). Form I packs with
a herringbone motif, while forms II and III display layered
structures.3,4 The structure of form I results in poor compacti-
bility, leading to poor tablet quality.3 However, diﬃculties in
producing suitable quantities of either form II or III have limited
research into their physical properties. While form III has been
reported as highly unstable in air, even being referred to as
‘elusive’,4 recent reports indicate that surfaces such as glass5 and
silica6 can promote its growth, and careful control of heating and
cooling rates during melt crystallisation have also been demon-
strated to lead to form III.7,8 Additionally, inclusion of hydroxy-
propyl methylcellulose (HPMC) into the paracetamol melts can
alter the kinetics of the crystallisation of the two metastable
phases, which provides an initial insight into the use of poly-
saccharides as templating agents.9,10
We report here the first air-stable formulations of paracetamol
form III based on an apparently active interaction with an
excipient matrix derived from saccharides. In situ spectroscopic
and diﬀraction studies have oﬀered unique insight into the melt
synthesis. Furthermore, this approach is shown to be amenable
to scale up.
The addition of molecular additives to alter the kinetics of
the crystallisation process to obtain metastable polymorphs has
been a frequent topic of study.11,12 The inhibition of the stable
phase through preferential interactions between the additive
and the surface available functional groups of the crystal may lead
to slowing of crystal growth,13–17 while preferential interaction of
the additive with the unstable phase may lead to stabilisation of
the phase or alter the balance of the kinetic rates of the two
phases.17 Design or selection of a suitable additive may then be
used to control the crystallisation processes and tailor the creation
of a desired polymorph.
Melt synthesis of air-stable form III utilises the sugar-based
excipients lactose monohydrate and HPMC. The crystallisation
process has been followed with simultaneous Raman-DSC and
time-resolved X-ray diﬀraction-DSC experiments. Critically,
computational modelling of the interfacial interactions at the
predicted major faces of the respective paracetamol crystals and
the excipient indicate significant drivers to the stabilisation of
form III through hydrogen bonding.
Samples of paracetamol and an excipient (10% w/w) were
subjected to heating and cooling cycles with the phase of the
crystal established with in situ Raman spectroscopy throughout the
heating cycles.‡ A standardised heating cycle was implemented:
(i) ambient to 180 1C at 10 1Cmin1 and held for 2minutes tomelt
the paracetamol and excipient mixture; (ii) quench cooling to
0 1C to generate an amorphous phase; (iii) reheating to 180 1C
at 10 1C min1. This last cycle caused three major thermal
events: an exotherm at ca. 90 1C corresponding to crystallisa-
tion [identified as form III with indicative Raman shifts of
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phenyl C–C (ca. 1620 cm1), amide II (ca. 1560 cm1), and
phenyl ring deformations (ca. 1320 and 1230 cm1) bands],8,18
a second exotherm at 133 1C (conversion to form II), followed by
an endotherm at 160 1C (melt of form II) (Fig. 1). The system
with HPMC shows essentially identical behaviour (ESI,† Fig. S1
cf. Fig. S2). By comparison, an excipient free sample (ESI,†
Fig. S3) melts on heating and cools to an amorphous phase.
Upon reheating, recrystallisation to form II occurs at ca. 83 1C
before the systemmelts at ca. 159 1C – importantly, no exotherm
is apparent at 133 1C.
A parallel study of the melt synthesis of form III with lactose
was undertaken using hyphenated in situ X-ray diﬀraction/DSC,
using similar protocols to those in DSC-Raman studies.§ Due
to a diﬀerence in the quenching rate, this sample results in a
mixture of amorphous/form II paracetamol at room temperature
as shown by the presence of Bragg reflections in the sample
(Fig. 2, top). Upon reheating of this sample, the DSC shows a
broad exotherm with a maximum at ca. 85 1C, followed by a
second exotherm at 130 1C and an endotherm at just below
160 1C. The latter corresponds to the melt of form II, and XRD
patterns collected above this temperature show no diﬀraction
features. The two exotherms correspond to distinct changes in
the XRD patterns. The first exotherm coincident with the
crystallisation of form III from the amorphous material present.
The second exotherm corresponds to the conversion of form III
present into form II, resulting in a pure form II above 130 1C
which persists until the mixture melts. Each pattern was
analysed using the Rietveld method (selected datasets are given
in the ESI,† Fig. S4 and Table S1). The presence of form II
throughout the experiment up to the melting point is clear, as is
the fact that form III grows in during the first exotherm and is
converted to form II at the second. The area under the diﬀrac-
tion pattern from each phase was calculated (ESI,† Fig. S5). It is
clear that the amount of form III present is largely constant
between the two exotherms, despite the fact that form II crystals
are also present. The amount of form II present increases
throughout the experiment until the second exotherm, presum-
ably a result of seeding of crystallisation from the amorphous
material (in contrast to the pure phase III inferred from the
Raman-DSC experiment in this region of the thermogram).
Thus the lactose additive is still able to stabilise form III even
in the presence of form II crystals.
Interactions between the sugar excipients (modelled as
lactose) and paracetamol were investigated computationally,¶
through the minimisation of the intermolecular interactions
between crystal surfaces of the diﬀering paracetamol polymorphs
and a lactose molecule. For forms I and III, the dominant crystal
Fig. 1 (a) DSC thermograms and (b) Raman spectra recorded at (i) 30 1C
before heating [form I], (ii) 30 1C after quench cooling [amorphous] and (iii)
110 1C [form III] after reheating for a 10% lactose containing sample of
paracetamol (annotated with key spectral shifts observed from I to III).
Fig. 2 Simultaneous XRD (top)-DSC (bottom) data collected on a sample
of paracetamol/lactose. The sample was heated to 180 1C, held at this
temperature for 2 min, and quenched before a second heating cycle
performed at 10 1C min1. The data shown are for this second heat.
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faces of each phase, as indicated by several morphology pre-
diction methods8 were investigated. For a single lactose mole-
cule, significantly stronger interactions are indicated with the
surfaces of form III compared to form I (Table 1). Visualisation of
the strongest interactions for both systems (Fig. 3) shows that the
match between hydrogen bond groups on each system is greater
for form III compared to form I. It appears that the repeat of the
location of the OH groups on this surface matches the lactose
molecule ensuring a number of hydrogen bonds can be formed
between the two systems. This matching of system size and
orientation of hydrogen bonding functional groups may be the
source of the stabilisation of form III and points to an active
role for the excipient in stabilising the metastable form.
The creation of form III was successfully scaled up using this
approach and 100 mg quantities have been reproducibly obtained
with the lactosemonohydrate system.** The stability of the obtained
formulation was characterised by XRD immediately after formation
and at periods throughout storage under standard ambient condi-
tions for greater than 12 months (Fig. 4). After 12 months, form III
shows partial transformation to other forms, but remarkably there
was retention of form III over this time scale.
The design of an air-stable formulation for paracetamol form
III has been developed with hyphenated thermo-spectroscopic
and thermo-diﬀraction experiments. Scale-up of the process yields
material that shows long-term stability for form III and is
obtainable reproducibly, albeit in a mixture with other forms
(for example, form II). Crucially, a match between the size of
the sugar excipient molecule and functional group types of the
surfaces of the form III crystals appears to be a major contribu-
tion to this stability. Therefore, an ‘active’ excipient template
that stabilises solid state forms inaccessible under ambient
conditions underpins this work. We aim to extend this approach
and further develop predictive computational tools that oﬀer a
new approach in designing formulations of metastable forms in
the future.
We thank Diamond Light Source for access to beamline I12
(EE-12735) the results from which contributed to the results
presented.
Notes and references
‡ DSC data were collected using TA Instruments Q2000 DSC with a RCS
90 cooling system with the samples run in open Tzero aluminium pans.
Approximately 6 mg of sample was used and each experiment was run in
duplicate. This was coupled with a Renishaw Portable Raman Analyzer
RX210 (785 nm laser, 100% laser power, 1 accumulation, 3 seconds
exposure time) for the in situ DSC-Raman analysis. The optical probe of
the system was held approximately 3 cm from the sample and a photo
calorimetry accessory was used in place of the DSC lid to allow access to
the sample but retaining accurate temperature control. During each DSC
cycle, Raman spectra were collected every 3 1C. Powder X-ray diﬀraction
data were collected using a Bruker D8 diﬀractometer in Bragg–Brentano
yy geometry with Cu Ka radiation (1.5418 Å) with a scintillation
counter. Data were collected in the 2y range 5 to 401 in steps of 0.051
with a 6 second count time.
§ In situ XRD-DSC was undertaken using Beamline I12 of the Diamond
Light Source. Full details of the apparatus will be reported elsewhere.19
In brief, a TA Instruments Q20 calorimeter was modified by drilling two
holes in the furnace head to permit the X-ray beam to penetrate it.
Samples of paracetamol/lactose (90/10 w/w, total mass ca. 20 mg) were
then heated at 10 1C min1 as for DSC-Raman work and 4 s diﬀraction
patterns collected on a Thales Pixium RF4343 detector every 6 s.
DSC data were analysed using the TA Instruments Universal Analysis
Table 1 Calculated interaction energies for lactose with paracetamol
surfaces
System Energy (kJ mol1)
Form I (001 surface) 42.748
Form I (011 surface) 51.321
Form III (001 surface) 55.693
Form III (010 surface) 57.735
Fig. 3 Comparison of the interaction between lactose molecule (yellow)
and: (a) (011) surface of form I; (b) the (010) surface of form III.
Fig. 4 Comparison of XRD patterns for paracetamol form III formulation
at (i) 0 days, (ii) 15 days, (iii) 32 days, (iv) 12 months and the simulated XRD
patterns for (v) form III, (vi) form II and (vii) form I.
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software, and XRD data using in house routines. Rietveld refinements
were performed using the GSAS and Topas Academic programmes.20
¶ The molecular modelling was carried out using the in-house program
DEX.21–23 The crystal structures of paracetamol polymorphs (form I
(HXACAN30),24 form II (HXACAN31)24 and form III (HXACAN29),4) were
extracted from the CSD,25 energy minimised using the downhill simplex
routine with in-house code using the potential described by No et al.26
using atomic point charges fitted to the electrostatic potential calcu-
lated for the isolated molecules in the program orca (mPW2PLYP-D3/
def2-TZVPPD).27–29 The interaction energy between the crystal surface
and a probe molecule was calculated in the same way and minimised
using the differential evolution (DE) optimisation algorithm30,31 by
alteration of the position and orientation of the probe molecule on
the selected crystal surface. The parameters were constrained to lie in
the range 5 to 5 Å for translations and 180 to 1801 for the rotations.
The control parameters for the DE algorithm (K, F, Gmax, Np) were set to
0.75, 0.75, 2000, 60. The underlying crystal surface was generated by
slicing a 3  3  3 crystal block through the selected surface removing a
3  3 layer.
8 Morphology predictions were carried out using BFDH and attach-
ment energy methods. Dreiding and COMPASSII force fields were used
with the relevant optimised crystal structure. Atomic point charges for
the Dreiding force field were taken from the electrostatic fit carried out
for the subsequent modelling. Resulting morphologies are presented
in ESI.†
** Production of form III at 100 mg scale was achieved by preparing a
physical mix of form I paracetamol and lactose monohydrate (10% w/w)
on a glass coverslip. This was subjected to a standard heating cycle
(ambient to 180 1C at 10 1C min1 (2 minute isotherm), followed by
quench cooling to 0 1C and reheating to 110 1C at 10 1C min1) in the
cell in DSC.
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